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Accepted 8 November 2012AbstractObjective: Cervicovaginal secretions (CVSs) are reported to protect against human papillomavirus (HPV) infection. Although vaginal douching
is known to clear both viral inoculants and CVSs, its effect on CVSs in women with HPV infection is unknown.
Materials and Methods: The in vitro HPV pseudovirus infection system was used to test the protective activity of CVSs against HPV infection in
samples collected before and after vaginal douching. To simulate different time points of vaginal douching in relation to viral exposure, the cell
CVS reconstitute was washed after different viral exposure durations.
Results: In the CVSs of premenopausal and postmenopausal women who did not perform douching, the CVSs inhibited HPV infection by
56.7  1.8% and 53.6  2.5%, respectively; in women who had performed douching, the CVSs inhibited HPV infection by only 31.2  7.1%,
which was significantly lower ( p < 0.01). Cell washing effectively cleared 60e90% of the infectious load with the greatest activity occurring
within 30 minutes after inoculation. In the presence of CVSs, a sustained inhibition of HPV infection existed for up to 8 hours after HPV
exposure, and cell washing increased the clearance to up to 82e93% of the infectious load.
Conclusion: This study confirms the protective activity of CVSs against HPV infection regardless of age. In this in vitro study, the net effect of
douching was found to be beneficial.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Infection by human papillomavirus (HPV), one of the most
common sexually transmitted infections, is necessary for cervi-
cal carcinogenesis. A global survey of HPV prevalence revealed
an overall prevalence rate (95% confidence interval) of 10.5%
(range: 9.9e11.0) [1]. With ample epidemiological evidences
suggesting sexual behavior as the primary risk factor for HPV
infection [2], the role of cervicovaginal secretions (CVSs) and
the effect of vaginal douching around sexual intercourse onHPV* Corresponding author. Department of Obstetrics and Gynecology,
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Notably, CVSs have selective antimicrobial activity against
nonresident bacterial species in the vagina [3]. Various antimi-
crobial substances in CVSs play important roles in innate host
defense of the lower genital tract [4]. For example, cationic
polypeptide components of CVSs, such as alpha defensins,
reportedly block 55% of in vitro HPV infections [5].
Vaginal douching is a common practice worldwide [6].
Frequent vaginal douching is associated with susceptibility to
infectious pathogens, such as Chlamydia, Gonococcus, and
human immunodeficiency virus [7e10], and increased risk for
pelvic inflammatory disease [6]. Studies that investigated the
effect of vaginal douching on HPV infection have produced
inconsistent results [11e13]. In addition, the relationship be-
tween vaginal douching and the prevalence of cervical cancercs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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should simultaneously clear both infectious agents and pro-
tective CVSs from a theoretical perspective, the net effect of
this practice is unknown and warrants thorough investigation.
Because the life cycle of HPV infection entirely relies on
differentiation of the squamous epithelial cells, HPVs are
difficult to propagate in culture. Detailed studies on the in-
fectious process and inhibitors of infection were not been
possible until studies on infectious HPV pseudovirus (PsV)
expressing fluorescence marker were performed to monitor
infectious events [16,17]. Like authentic HPV, the PsV has an
icosahedral capsid resembling that of the native HPV [18].
Apparently, PsVs precisely replicate the initial phases of HPV
infection, which makes them useful for elucidating HPV
infection mechanisms [19]. In a mouse cervicovaginal infec-
tion model, Roberts et al [20] reported that mechanical
disruption of the vagina enhances HPV infectivity and that the
infectivity can be blocked by peptide antibiotics such as alpha
defensins [5].
In this in vitro study, the effects of CVSs, which along with
infectious agents, are readily cleared by douching, were
analyzed in terms of their effects on infectivity of HPV PsV by
simulating the effects of douching performed at different times
after viral exposure.
Materials and methodsClinical data and specimen collectionThe CVS samples used in this study were collected before
and after vaginal douching in eight premenopausal and eight
postmenopausal women who had undergone regular Pap smear
tests. After giving written informed consent, each woman
underwent a cervical scraping for a Pap smear test. The CVS
samples were collected by gently and systemically swabbing
the cervicovaginal mucosa with a cytobrush. The same pro-
cedure was repeated with a second cytobrush. The vagina and
cervix were then douched two times with a 3-cm sponge fully
rinsed with normal saline. The CVSs were then collected again
using the same procedure. The two cytobrushes containing
CVSs were transferred into a centrifuge tube containing 3 mL
phosphate-buffered saline (PBS) and stored at 80C before
use. This study was approved by the Institutional Review
Board of the Tzu Chi General Hospital, Hualien, Taiwan.Production of HPV 16 PsVsThe 293TT cell transfection method was used for efficient
production of HPV 16 PsVs [21]. Plasmids (p16Shell) encoding
codon-modified HPV 16 L1/L2 structure genes were co-
transfected with a 5.9-kb target plasmid (pfwB) that expresses
enhanced green fluorescent protein (GFP) under the control of
human elongation factor 1 alpha promoter [17]. The HPV 16
L1/L2 vector (p16Shell) and GFP plasmid were provided by Dr
Schiller [14]. Maps of L1/L2 vector (p16Shell) and GFP
plasmid can be found at http://home.ccr.cancer.gov/lco/target.
htm. Transfection, production, and harvest of PsVs from the293TT cells were performed according to protocols posted
online. The harvested PsVs were purified by iodixanol (Opti-
Prep, Axis-Shield) gradient centrifugation and allowed to
mature in vitro [17]. The virus titer was determined using 293TT
cells as targets and was calculated using the following formula:
(1  105 cells)  (1000 mL/mL)  (dilution factor)  (fraction
of cells expressing GFP)¼ transducing units per milliliter (TU).PsV infection assayA 1:1 dilution of CVSs in PBS was filtered through a 0.45-
mm filter before the experiments. For the PsV infection assay,
1.2  105 TU of PsVs in 500 mL PBS or filtered CVSs were
inoculated into 1  105 HeLa cells grown overnight in a six-
well plate. After 48 hours, the cells were trypsinized, and the
proportion of GFP-positive cells (i.e., the infection ratio) was
determined by flow cytometry. A potent HPV inhibitor, 1%
carrageenan [20], was used as the control. The inhibition
percentage was calculated using the following formula: 100 
[1  (net percentage of GFP cells in test/net percentage of
GFP cells in mock)]. To determine the period of inoculant
removal, HeLa cells were washed once with PBS and fed with
a fresh medium at different time points after inoculation. The
infection ratio was determined at 48 hours. Experiments were
repeated in triplicate. The typical infection ratio in the
resulting PsVs was 20e30%.Statistical analysisProportions of inhibition activity by CVSs and the effects
of vaginal douching on infection ratios were compared by z
test in a time-course study. All statistical analyses were per-
formed using SAS software (version 8.2; SAS Institute, Inc.,
Cary, NC, USA). A p value less than 0.05 was considered
statistically significant.
ResultsCVSs protected cells from HPV16 PsVs infectionThe inhibiting effects of the CVSs on HPV infection were
tested in cultured cells through in vitro assays of PsV. The
CVSs from premenopausal and postmenopausal women
inhibited HPV infection by 56.7  1.8% and 53.6  2.5%,
respectively (Fig. 1). The CVSs collected after vaginal
douching had a significantly decreased inhibition ratio of
31.2  7.1% ( p < 0.01). In comparison, carrageenan, a known
HPV infection inhibitor [20], inhibited infection by
98.2  1.0%. The experimental results showed that the pro-
tective activities of CVSs against HPV infection are modest
compared with those of carrageenan.Protective effects of CVS at different viral exposure
durationsVaginal douching may be beneficial by removing HPV
from the place of infection and by shortening the duration of
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Fig. 1. Inhibiting activity of cervicovaginal secretions (CVSs) against human papillomavirus pseudoviruses (HPV PsVs) infection. (A) The HeLa cells were
infected with green fluorescent protein-expressing HPV16 PsVs (PsV) in the presence or absence of CVS or 1% carrageenan (Carra) and then observed under a
fluorescence microscope. (B) Inhibiting effects of CVSs on PsV infection in premenopausal (pre-MP) and menopausal (MP) women before and after vaginal
douching. Carrageenan (1%) served as the positive control. *p < 0.01.
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douching before intercourse when CVSs are cleared, and after
intercourse when inoculated viruses are cleared. To mimic this
scenario in vitro, PsVs were inoculated into cervical cells in
the absence of CVSs and were washed off at different time
points to shorten the duration of viral exposure. Early removal
of inoculants markedly decreased infectivity to as low as 10%
(Fig. 2), that is, 90% of the infectious load was cleared. This
clearance effect was greatest within the first 30 minutes after
inoculation. When cell washing was performed as late as 8hours after inoculation, the clearance effect reduced to 60%
(Fig. 2).
In the other mimicked scenario in which CVSs were pre-
sent, the PsV-inoculated cervical cells showed a steady sup-
pression of infectivity in general for up to 8 hours after
inoculation. The effect of cell washing on inhibiting PsV
infection was over 90% within 4 hours and over 80% at the 8th
hour (Fig. 2). These experimental results indicate that CVSs
have a general protective effect, and early douching after
exposure helps to reduce the infectious load.
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Fig. 2. Effect of time-course removal of inoculants in the presence or absence
of cervicovaginal secretions (CVSs). The human papillomavirus pseudoviruses
in the presence of CVSs or phosphate-buffered saline (PBS) were removed
from cell cultures by washing with PBS at 1 minute, 10 minutes, 30 minutes, 1
hour, 2 hours, 4 hours, and 8 hours after inoculation; infection ratios in HeLa
cells were measured at 48 hours. Infection ratios with inoculants not removed
in the presence of PBS and CVSs were 18.0  0.4% and 6.1  0.2%,
respectively. *p < 0.05.
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This study explored the net effects of vaginal douching on
HPV infection. A nationwide investigation of adult women in
Taiwan demonstrated that 65% of Taiwan women douche [22].
Surveys show that most women use tap water, and <8% use
feminine hygiene products [11]. Relatively higher rates of
vaginal douching have been reported in developing countries
such as Cambodia [23] and countries in the sub-Saharan Af-
rican regions [10,24], where most adult women routinely
practice douching.
By clearing the mucus barrier of CVSs and by disturbing
innate immunity, vaginal douching may facilitate acquisition
of HPV. However, this practice also reduces the infectious load.
Epidemiological studies on the relationship between vaginal
douching and HPV infection have produced conflicting results
[11e13]. The in vitro HPV PsVs infection assay performed in
this study revealed the net effect and the importance of timing
of vaginal douching on HPV infection. Comparisons of CVSs
data collected from women before and after vaginal douching
showed that douching reduced infection rates by one-half. This
finding is supported by a mouse model showing a high rate of
HPV PsVs infection after vaginal brushing and a still higher
rate of infection after using a vaginal microbicide [20].
Previous epidemiological studies have identified a second
peak prevalence of HPV infection in older women, but the
reason for the prevalence is unknown [2]. Among the different
causes speculated, atrophy of the genital mucosa with a
compromise of innate immunity is a likely cause. The CVSs
collected from premenopausal and postmenopausal women in
this study showed similar inhibiting effects on HPV infection,
which excludes the possibility of a differing antiviral activity
between pre menopause and postmenopause.This study evaluated postcoital douching performed at
different times after viral exposure by simulating the washing
of host cells exposed to HPV for different periods. Experi-
ments were performed in the absence of CVSs to simulate
those areas that are not exposed to CVSs, for example, the
vulva, and were also performed in the presence of CVSs to
simulate the exposed areas such as the cervix and vagina. In
the absence of CVSs, early washing reduced virus infectivity.
Notably, 90% of viral infections were prevented when washing
was done within the first 30 minutes after HPV exposure. This
protection time window is consistent with the kinetics of early
HPV infection; a critical period of approximately 30 minutes
is needed for viruses to attach to cells [25,26]. This study
shows that cleansing of HPV inoculants from the skin is most
effective if washing is performed within 30 minutes. This
study also showed that CVSs have a sustained inhibiting effect
on HPV infection. In the presence of CVSs, HPV infection
became very inefficient. Depending on the duration of viral
exposure, CVSs protected against >90% of HPV infection in 4
hours and >80% of infection in 8 hours.
Clearly, this in vitro study is missing a number of important
elements in the real life, such as de novo production of CVSs
and continuous inoculation during sexual exposure. In addi-
tion, in the real life, vaginal douching may cause microtrauma
to the vaginal mucosa, which is essential for HPV entry [19].
Microtrauma may facilitate self-inoculation of HPV that
already exists in mildly dysplastic lesions, which typically
hosts a highly productive virus life cycle. This explains the
risky effect of vaginal douching on the persistence of low-grade
squamous intraepithelial lesions in a large-cohort study [22].
In summary, this study provides in vitro evidence of a
sustained protective role of CVSs, which is not adversely
affected by vaginal douching. In areas lacking CVSs, a golden
cleansing period of 30 minutes effectively prevents HPVentry.
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